Overview

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cediranib together with temozolomide and radiation therapy may kill more tumor cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Cediranib
Dacarbazine
Deoxyglucose
Fluorodeoxyglucose F18
Maleic acid
Temozolomide